CONFIDENTIAL  Proto col RMFPC -27 
Version 1.0   17 December 2020 
Rockwell Medical Inc.  1 Triferic AVNU infusion via Freedom Pump During Hemodialysis  
Protocol Title:  Triferic AVNU Infusion via Freedom Pump during Hemodialysis 
An open-label clinical study to evaluate the delivery of Triferic AVNU intravenously using the 
Freedom Pump-[ADDRESS_1220588]-dialyzer blood lines. 
Intervention Model:  
Cross -over: Participants receive alternative interventions during sequential hemodialysis 
treatments.  
Primary Purpose:  
Device Feasibility: An inte rvention of the Freedom P ump -[ADDRESS_1220589]-dialyzer blood lines .  this study 
will confirm the design and operating specifications of a device in hemodialysis patients . 
Study Phase:  Post marketing  
Study to assess feasibility of an approved device to administer an approved drug in hemodialysis patients.  
Number of Arms : 
2 Arms:  Infusion to Pre -dialyzer and Post-dialyzer blood lines. 
Masking:  
No masking Health Measurement/Observation:  
The ability to deliver the full dose of Triferic AVNU during the hemodialysis procedure. 
Intervention Name:  
[CONTACT_873957]:  Ferric Pyrophosphate Citrate Injection  
Freedom Edge® Syringe Driver F10020  
Intervention Form:  Solution for intravenous injection 
Participant Se x:  
Male and Female  
Participant Age Range:  ≥ 18 years of age,  
Condition/Disease:  
End-stage kidney disease on chronic hemodialysis (CKD_HDD). 
 
CONFIDENTIAL  Proto col RMFPC -27 
Version 1.0   17 December 2020 
Rockwell Medical Inc.  2 Protocol Number:  RMFPC -27 
Amendment Number:  N/A 
Compound: Triferic AVNU (Ferric Pyrophosphate Citrate injection).  
Brief Title:   
Triferic AVNU Freedom Pump Evaluation 
Study Phase: IV  
Study to assess feasibility of an approved device to administer an approved drug in hemodialysis 
patients.  
Sponsor Name: [CONTACT_873958]:   
Freedom Pu mp Manufacturer:  
KORU Medical Systems  
[ADDRESS_1220590] 
Chester, NY [ZIP_CODE]  [LOCATION_003] 
Tel: 1 -[PHONE_18104] 
Regulatory Agency Identifier Number(s)  
NDA: 212860 
Approval Date: 27 March 2020 
  
CONFIDENTIAL  Proto col RMFPC -27 
Version 1.0   17 December 2020 
Rockwell Medical Inc.  3  
Sponsor Signatory: 
I, the undersigned, have read and approve this protocol and agree on its content. It is confirmed 
that the information and guidance given in this protocol complies with scientific principles, the 
guidelines of Good Clinical Practice, the Declaration of Helsinki in the latest relevant version, 
and the applicable legal and regulatory requirements. 
  
 
  
Raymond D Pratt, MD  Chief Development Officer   Date  
 
 
  
 
  
 
Medical Monitor Name [CONTACT_9352] [CONTACT_7171]: 
Raymond D Pratt, MD  Rockwell Medical Inc  
[ADDRESS_1220591]. Wixom MI [ZIP_CODE] Tel: [PHONE_14584] X405 
CONFIDENTIAL  Proto col RMFPC -27 
Version 1.0   17 December 2020 
Rockwell Medical Inc.  4 INVESTIGATOR PROTOCOL AGREEMENT  
 
Protocol Title:  Triferic AVNU Infusion via Freedom Pump during Hemodialysis  
Protocol Number:  RMFPC -27 Version: 1.0 
 
 
By [CONTACT_27616], I  
• Confirm that my staff and I have carefully read and understand this protocol or 
protocol amendment and are thoroughly familiar with the appropriate use of the investigational drug described herein. 
• Agree to comply with the conduct and terms of the study specified herein and with any other study conduct procedures provided by [CONTACT_1034], Rockwel l Medical.   
• Agree to assume responsibility for the proper conduct of the study at this site, including complying with EMA guidelines, China Food and Drug Administration (CFDA) regulations, the International Conference on Harmonization (ICH) GCP 
guidelines, the Declaration of Helsinki, and all applicable rules, regulations, and 
federal, state, and local laws relating to the conduct of clinical studies and the protection of human Patients.  
• Agree not to implement deviations from or changes to the protocol or protocol amendments without agreement from the Sponsor and prior submission to and written approval (where required) from the Institutional Review Board (IRB) or Ethics 
Committee (EC), except when necessary to eliminate an immediate hazard to the 
Patients , or for administrative aspects of the study (where permitted by [CONTACT_87465]).  
• Agree to onsite monitoring of the case report forms (CRFs) and source documents by [CONTACT_873942], including but not limited to the EMA, CFDA, local governing regulatory bodies, and IRB/EC inspectors. 
   
Investigator's Signature   [CONTACT_873959]: 
CONFIDENTIAL  Proto col RMFPC -27 
Version 1.0   17 December 2020 
Rockwell Medical Inc.  5 Table of Contents  
1. Protocol Summary ..........................................................................................................8  
1.1. Synopsis ............................................................................................................................8  
1.2. Schema  ............................................................................................................................10  
1.3. Schedule of Events (SoE) ...............................................................................................11  
2. Introduction ...................................................................................................................12  
2.1. Study Rationale ...............................................................................................................12  
2.2. Background .....................................................................................................................12  
2.3. Benefit/Risk Assessment  ................................................................................................12  
2.3.1.  Benefit Assessm ent .........................................................................................................13  
2.3.2.  Overall Benefit: Risk Conclusion  ...................................................................................13  
3. Objectives  ......................................................................................................................14  
4. Study Design  ..................................................................................................................16  
4.1. Overall Design  ................................................................................................................16  
4.2. Scientific Rationale for Study Design  ............................................................................16  
4.3. Justification for Dose ......................................................................................................16  
4.4. End of Study Definition ..................................................................................................16  
4.5. Study Population .............................................................................................................16  
4.6. Inclusion Criteria  ............................................................................................................16  
4.7. Exclusion Criteria  ...........................................................................................................16  
5. Study Intervention(s) and Concomitant Ther apy .....................................................17  
5.1. Study Intervention(s) Administered................................................................................17  
5.1.1.  Medical Devices ..............................................................................................................17  
5.2. Preparation/Handling/Storage/Accountability ................................................................18  
5.3. Measures to Minimize Bias: Randomization and Blinding  ............................................18  
5.4. Study Intervention Compliance ......................................................................................18  
5.5. Dose Modification ..........................................................................................................18  
5.5.1.  Retreatment Criteria  ........................................................................................................18  
5.6. Continued Access to Study Intervention after the End of the 
Study ...............................................................................................................................18  
6. Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal........................................................................................20
 
6.1. Discontinuation of Study Intervention ............................................................................20  
6.1.1.  Temporary Discontinuation ............................................................................................20  
6.1.2.  Rechallenge  .....................................................................................................................20  
6.2. Participant Discontinuation/Withdrawal from the Study  ................................................[ADDRESS_1220592] to Follow up ............................................................................................................20  
7. Study Assessments and Procedures .............................................................................21  
7.1. Efficacy Assessments  .....................................................................................................21  
7.2. Safety Assessments  .........................................................................................................21  
7.2.1.  Physical Examinations ....................................................................................................21  
7.2.2.  Vital Signs  .......................................................................................................................21  
7.2.3.  Clinical Safet y Laboratory Assessments ........................................................................21  
CONFIDENTIAL  Proto col RMFPC -27 
Version 1.0   17 December 2020 
Rockwell Medical Inc.  6 7.2.4.  Pregnancy Testing ...........................................................................................................22  
7.3. Adverse Events (AEs), Serious Adverse Events (SAEs), and 
Other Safety R eporting ...................................................................................................22  
7.3.1.  Time Period and Frequency for Collecting AE and SAE Information  .....................................................................................................................22
 
7.3.2.  Method of Detecting AEs and SAEs ..............................................................................22  
7.3.3.  Follow-up of AEs and SAEs  ...........................................................................................22  
7.3.4.  Regulatory Reporting Requirements for SAEs ...............................................................23  
7.3.5.  Pregnancy  ........................................................................................................................23  
7.3.6.  Disease- Related Events and/or Disease- Related Outcomes Not 
Qualifying as AEs or SAEs.............................................................................................24  
7.3.7.  Medical Device Deficiencies  ..........................................................................................24  
7.4. Pharmacokinetics  ............................................................................................................25  
7.5. Genetics and/or Pharmacogenomics ...............................................................................25  
7.6. Biomarkers  ......................................................................................................................25  
7.7. Immunogenicity Assessments.........................................................................................26  
7.8. Medical Resource Utilization  .........................................................................................26  
7.9. Statistical Hypotheses  .....................................................................................................26  
7.10.  Sample Size Determination  ............................................................................................26  
7.11.  Analys is Sets  ...................................................................................................................26  
7.12.  Statistical Analyses  .........................................................................................................26  
7.12.1.  General Considerations ...................................................................................................26  
7.12.2.  Primary Endpoint(s) ........................................................................................................26  
7.12.3.  Secondary Endpoint(s) ....................................................................................................26  
7.12.4.  Safety Analysis  ...............................................................................................................27  
7.12.5.  Other Analysis ................................................................................................................27  
8. Supporting Documentation and Operational Considerations  ..................................28  
8.1. Regulatory, Ethical, and Study Oversight Considerations .............................................28  
8.1.1.  Regulatory and Ethical Considerations ...........................................................................28  
8.1.2.  Financial Disclosure ........................................................................................................28  
8.1.3.  Informed Consent Process ..............................................................................................28  
8.1.4.  Data Protection ................................................................................................................29  
8.1.5.  Committee s Structure ......................................................................................................29  
8.1.6.  Dissemination of Clinical Study Data .............................................................................29  
8.1.7.  Data Quality Assurance  ..................................................................................................29  
8.1.8.  Source Documents ..........................................................................................................30  
8.1.9.  Study and Site Start and Closure ....................................................................................30  
8.1.10.  Publication Policy  ...........................................................................................................31  
8.2. Clinical Laboratory Tests ................................................................................................31  
8.3. AEs and SAEs: Definit ions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ............................................................................32  
8.3.1.  Definition of AE .............................................................................................................32  
8.3.2.  Definition of SAE ...........................................................................................................33  
8.3.3.  Recording and Follow -Up of AE and/or SAE ................................................................34  
8.3.4.  Reporting of SAEs ..........................................................................................................36  
CONFIDENTIAL  Proto col RMFPC -27 
Version 1.0   17 December 2020 
Rockwell Medical Inc.  7 8.4. AEs, ADEs, SAEs, SADEs, [LOCATION_003]DEs and Device Deficiencies: 
Definitions  and Procedures for Recording, Evaluating, Follow-
up, and Reporting in Medical Device Studies ................................................................36  
8.4.1.  Definition of Medical Device AE and ADE ...................................................................36  
8.4.2.  Definition of Medical Device SAE, SADE and [LOCATION_003]DE ...............................................37  
8.4.3.  Definition of Device Deficiency  .....................................................................................38  
8.4.4.  Recording and Follow -Up of AE and/or SAE and Device 
Deficiencies .....................................................................................................................38  
8.4.5.  Reporting of SAEs ..........................................................................................................40  
8.4.6.  Reporting of SADEs .......................................................................................................40  
8.5. Protocol Amendment History .........................................................................................41  
9. Triferic AVNU US PI  ...................................................................................................42  
10. Freedom Edge Pump  ....................................................................................................43  
 
CONFIDENTIAL  Proto col RMFPC -27 
Version 1.0   17 December 2020 
Rockwell Medical Inc.  8 1. Protocol Summary  
1.1. Synopsis  
Protocol Title:   
Triferic AVNU In fusion via Freedom Pump During Hemodialysis  
An open-label clinical study to evaluate the delivery of Triferic AVNU intravenously using the 
Freedom Pump-[ADDRESS_1220593]-dialyzer blood lines. 
Intervention Model:  
Cross -over: Participants receive alternative interventions during sequential hemodialysis 
treatments.  
Primary Purpose:  
Device Feasibility: An intervention of the Freedom Pu mp -[ADDRESS_1220594]-dialyzer blood lines .  this study 
will confirm the design and operating specifications of a device in hemodialysis patients. 
Brief  Title:  Trife ric AVNU F reedom Pump Administration  
Rationale: Triferic AVNU is approved for IV infusion direct into the pre- or post-dialyzer bloodlines over [ADDRESS_1220595] an on-machine syringe pump, an 
external pump is required to adm inister Triferic AVNU.  This study will explore the feasibility of 
using an external mechanical syringe pump to deliver the approved dose of Triferic AVNU (6.75 mg Fe/4.5 mL). 
Objectives and Estimands :  
 
Objectives  Estimands  
Primary   
• Time for complete in fusion of 4.[ADDRESS_1220596]- Dialyzer  • At 2 mL/hr  infusion rate total volume 
to be delivered at 2.25 ± 0.3 hr 
Secondary   
• Mean ∆ sFe pre -Dialyzer and post -
Dialyzer  • Mean ∆sFe pre -Dialyzer and post 
Dialyzer are equal ± 15%  
• Mean TSA T Max pre -Dialyzer and 
post- Dialyzer  • TSAT max does not exceed 100%  
Safety   
CONFIDENTIAL  Proto col RMFPC -27 
Version 1.0   17 December 2020 
Rockwell Medical Inc.  9 • Adverse Events  • Number of adverse events overall  
• Number of adverse events related to 
device  
 
Overall Design : 
Brief Summary : 
This is an open label 6 period crossover study to examine the feasibility of using an external 
spring-driven infusion pump (Freedom Edge-20) to administer Triferic AVNU intravenously in 
the pre- and post-dialyzer blood lines in subjects undergoing chronic hemodialysis.  
Study Duration: Patients will be in the study for a ma ximum of up to 21 days.. 
Treatment Duration : Treatment duration will be 6 HD sessions.   
Health Measurement/Observation : The study will examine the delivery of Triferic AVNU, 4.[ADDRESS_1220597]-dialyzer blood lines using the Freedom 
Edge 20 pump.  The time for delivery at a nominal rate of 2 mL/hr will be assessed along with 
the maximum sF e and TSAT achieved at the end of the infusion.  Because the duration of 
infusion is slightly shorter than recommended in the approved product labeling, the effect on iron parameters will be compared to published data for continuous infusion over 3 hours. 
Visit Frequency : Patients will be assessed at 6 consecutive HD  sessions.  The site of infusion 
(pre or p ost-dialyzer) will be alternated at each HD session so that at eh end of the study each 
patient will receive Triferic AVNU infused IV into pre-dialyzer and post-dialyzer blood lines 3 
times each.  A total of 10 subjects will participate in this study.  
Numb er of Participant s: 
A maximum of  12 participants will be enrolled to study intervention such that approximately 10 
evaluabl e participants complete the study.  
Intervention Groups  and Duration: 
All patients will rec eive Triferic AVNU at each of 6 HD session s.   
Data Monitoring/Other  Committee: No  
CONFIDENTIAL  Proto col RMFPC -27 
Version 1.0   17 December 2020 
Rockwell Medical Inc.  10 1.2. Schema  
 
 

CONFIDENTIAL  Protocol [protocol number]  [version and/or identifie r] 
 
Rockwell Medical Inc.  11 1.3. Schedule of Events  (SoE) 
Table 1:  Schedule of Events.  
Procedure  Screening  
(up to 7 days before Day 1)  Interventional Period (HD Days)  Follow-up ([ADDRESS_1220598] dose) or E/D = Early 
Discontinuation  
[ADDRESS_1220599] 
(WOCBP only)  X        
Laboratory tests (CBC, Serum 
iron profile)  X       X 
Vital signs (pre and post HD) X X X X X X X  
Study intervention   =========================   
Infusion Duration (min.)   X X X X X X  
AE review   =========================   
Administration events   =========================  X 
Adverse events   =========================  X 
Device d eficiencies   =========================  X 
HD Parameters (Qb,Qd, 
arterial machine pressure , 
venous machine pressure)   =========================  X 
Iron profile : pre-Dialysis   X X X X X X  
Iron profile : End of Infusion   X X X X X X  
CONFIDENTIAL  Protocol RMFPC -27 
 
 12 2. Introduction  
Trife ric AVNU (Ferric Pyrophosphate Citrate) injection for intravenous use, is the intravenous 
formulation of Triferic.  Triferic AVNU delivers quantitatively the same amount of iron as 
delivered through the dialysate (6.5 mg Fe/HD).  Triferic AVNU should be administered as a 
slow infusion into the pre-dialyzer or post-dialyzer blood line over 3 hour s.  Triferic is indicated 
for the maintenance of iron and hemoglobin in patients on chronic hemodialysis.  The safety 
profile of Triferic AVNU is the same as Triferi c for hemodialysate in that the same amount of 
iron is delivered with each treatment type.  
2.1. Study Rationale  
During the development of Triferic AVNU, the drug was delivered using the on- machine syringe 
pump programmed to deliver the volume of the ampule (4.5 mL) over [ADDRESS_1220600]-dialyzer blood 
line. 
2.2. Background  
Triferic (Ferric Pyrophosphate Citrate) is a novel iron replacement product indicated  to maintain 
hemoglobin concentrations in patients receiving chronic hemodialysis.  Triferic in conjunction with erythropoiesis stimulating agents maintains hemoglobin by [CONTACT_873943], on-average, during a hemodialysis session.  Triferic delivers 100% bioavailable iron by 
[CONTACT_873944].  Triferic administers approximately 6.5 mg of ir on (III) with each treatment.  Triferic AVNU is 
the intravenous presentation of Triferic.  Triferic AVNU was approved in March 2020 based on a clinical equivalence s tudy demonstrating delivery of iron intravenously matching the delivery of 
iron from the di alysate.   
2.3. Benefit/Risk Assessment  
• Triferic is approved as an iron replacement product to maintain hemoglobin and iron 
stores in patients receiving chronic hemodialysis when administered via the dialysate.  Triferic AVNU is the intravenous presentation of Triferic and was approved by [CONTACT_873945].  Triferic AVNU can be administered as a slow infusion over [ADDRESS_1220601] -dialyzer blood line.   
• The safety profiles of Triferic and T riferic AVNU are similar to placebo.  Full 
prescribing information is included in the approved product labeling for both products.  There are no contraindications to the use of Triferic or Triferic A VNU. 
• The Freedom Edge Pump is approved for the infusion of prescribed liquid medicines.  It is self -contained  and can administer liquid medicines at a constant infusion rate which is 
determined by [CONTACT_873946].  The Freedom Edge pump is approved in the US.  
CONFIDENTIAL  Protocol RMFPC -27 
 
 13 More detailed information about the known and expected benefits and risks and reasonably 
expected  adverse events of Triferic and Triferic AVNU  may be found in the Package Insert  
(Section 9) .  Information and  instructio ns for use for the Freedom Edge Pump are  ( IDFU ) can be 
found in the instruction brochure ( Section 10)  and  online at 
https://www.korumedical.com/products/freedomedge. 
2.3.1. Benefit Assessment  
Objectives for this study are to establish the ability of the Freedom Edge Pump to deliver the dose of Triferic AVNU over a period of 2 to 3 hours as a continuous infusion. 
All products are approved for use in the [LOCATION_003] 
The benefits of using Triferic AVNU with the Freedom pump is to provide a maintenance dose 
of iron primarily in patients who dialyze on machines that use solid bicarbonate. 
This study will confirm the safety of Trifer ic AVNU adm inistered as a continuous infusion using 
the Freedom Edge pump. 
2.3.2. Overall Benefit: Risk Concl usion 
The benefit of this study will be to demonstrate an alternate means to d ose Triferic AVNU to 
patients on chronic hemodialysis.  Currently, the product labeling for Triferic AVNU indicates 
that the product is to be infused over [ADDRESS_1220602] a syringe pump, or the pump is otherwise used for administration of heparin. 
The risks to patients ar e minimal.  The main risk identified is the inability to deliver the entire 
dose of Triferic AVNU over the 2 to 3-hour duration.  The consequences of a missed dose of 
Triferic AV NU are minimal since only small quantities of iron are administered at each HD .  
Should the iron dose not be administered, patients can receive their usual dose of macromolecular iron at the next scheduled administration time. 
CONFIDENTIAL  Protocol RMFPC -27 
 
 14 3. Objectives  
• Investigate the administration of Triferic AVNU by [CONTACT_873947]  
• Validate the administration rates int the pre - and post-dialyzer blood lines when using the 
2 mL/hr line set.  
• Investigate the maximum serum iron and TSAT concentrations. 
• Investigate the useability of the Freedom Edge Pump in the setting of a dialysis unit to 
administer Triferic AVNU IV.  
 
Table 2:  Objectives and Estimands.  
Objectives  Estimands  
Primary   
• Time for complete infusion of 4.[ADDRESS_1220603] -Dialyzer • At 2 mL/hr infusion rate total 
volume to be delivered at 2.25 ± 
0.3 hr 
Secondary   
• Mean ∆ sFe pre -Dialyzer and post -
dialyzer  • Mean ∆sFe pre -Dialyze r and post 
dialyzer are equal ± 15%  
• Mean TSAT Max pre -Dialyze r and 
post- Dialyzer  • TSAT max  does not exceed 100%  
Safety  •  
• Adverse Events  • Number of adverse events overall  
• Number of adverse events related to device 
 
 15  
 
 16 4. Study Design  
4.1. Overall Design  
• Single site open -label repeated crossover.  
• 10 subjects on chronic HD  
• 3 doses of  Triferic AVNU administered via Freedom Edge pump into the pre- dialyzer 
blood line  
• [ADDRESS_1220604]- dialyzer 
blood line  
• Pre-dialysis and End -of-Infusion serum iron profiles at each  
• Adverse events reported during each HD. 
• Device issues reported with each HD.  
4.2. Scientific Rationale for Study Design  
• All products and devices are approved and used according to their labeling 
• This study will confirm the utility of the Freedom Edge pump to administer intravenous 
medications during a hemodialysis session.  
4.3. Justification for Dose  
• The dose of Triferic AVNU (6.75 mg Fe) is the approved adult dose. 
• The Freedom Edge pump is calibrated  to deliver medications at various rates  and is 
approved for such administrations. 
4.4. End of Study  Definit ion 
A participant is considered to have completed the study if he/she has completed all study visits. 
4.5. Study Population  
Adult age >18 years receiving chronic hemodialysis 3X/week. 
4.6. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
1. Participant must be 18 years of age inclusive, at the time of signing the informed consent. 
2. Receiving chronic hemodial ysis for 3 -4 hours each session 3x/week. 
3. Medically stable according to the investigator opi[INVESTIGATOR_1649] 4. Capable of giving signed informed consent which includes compliance with the 
requirements and restrictions listed in the informe d consent form (ICF) and in this protocol. 
 
4.7. Exclusion Criteria  
1. Hemodynamically unstable during hemodialysis 
2. Evidence of active bleeding from the GI tract.  
 
 17 5. Study Intervention(s) and Concomitant Therapy  
Study intervention is defined as an y investigational intervention(s), mark eted product(s), 
placebo , or medical device(s) intended to be administered to a study participant according to the 
study protocol. 
5.1. Study Intervention(s) Administered  
 
ARM Name  [CONTACT_183172]-Dialyzer Infusion and Post- Dialyzer inf usion  
Intervention Name [CONTACT_873960] 6.75 mg Fe/4.5 mL pre-dialyzer blood line 
infusion 
Type  Drug / Device 
Dose Formulation Solution 
Unit Dose Strength(s)  6.75 mg Fe/4.5 mL 
Dosage Level(s) 6.75 mg IV/HD 
Route of Administration  IV Infusion  
Use Feasibility of administration with Freedom Edge pump  
IMP and NIMP  Triferic AVNU  
Sourcing  Triferic AVNU Provided by [CONTACT_873948]. 
Freedom Edge pump provided by [CONTACT_873949]. Each pouch is labeled as required for the approved product 
5.1.1. Medical Devices  
1. The medical device provided for use in this study are Freedom Edge pump manufactured by 
[CONTACT_873950], Chester NY [ZIP_CODE] [LOCATION_003]. 
2. Instructions for medical device use are provided in the instruction manual shipped with the device. 
3. Precision flow rate tubing sets for administration rate of 2 mL/hour will be provided by [CONTACT_873951] [ZIP_CODE]. 
4. Instructions for connecting the tubing to the syringe and the Freedom Edge pump are provided in Section 10 
 
 18 5. All device deficiencies (including malfunction, use error and inadequate labelling) shall be 
documented and reported by [CONTACT_31819] (see Section 7.3.7) and appropriately managed by [CONTACT_456]. 
5.2. Preparation/Handling/Storage/Accountabili ty 
1. The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study intervention received and any discr epancies are 
reported and resolved before use of the study intervention. 
2. Only participants who have signed an informed consent may receive study intervention and only authorized site staff may supply or administer study intervention. All study intervention must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff.  
3. The investigator, institution, or the hea d of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition rec ords).  
5.3. Measures to Minimize Bias: Randomization and Blinding  
Open -label, No 
blinding at site 
level  This is an open- label stu dy 
5.4. Study Intervention Co mpliance  
When participants are dosed at the site, they will receive study intervention directly from the investigator or designee, under medical supervision. The dat e and time of each dose administered 
in the clinic will be recorded in the source documents and recorded  in the CRF. The dose of 
study intervention and study participant identification will be confirmed at the time of dosing by a member of the study site s taff other than the person administering the study intervention. 
A record of the quantity  of Triferic AVNU and the duration of infusion administered to  each 
participant must be maintained and reconciled with study intervention and compliance records.  Intervention start and stop dates, including dates for intervention delays and/or dose reductions 
will also be recorded.  
5.5. Dose Modification  
No dose modifications are allowed, if a subject does not tolerate the dose, they will be discontinued from the study. 
5.5.1. Retreatment Criteria  
All participants entered in the study will be treated at HD # 1 to 6. Throughout the study, study intervention will be  open label.  
5.6. Continued Access to Study Intervention after the End of the Study  
 
 19 At the end of this study, subjects may continue to receive Triferic AVNU via the Freedom Edge 
pump at the discretion of the Investig ator.  Triferic AVNU will be provided by [CONTACT_1034] 
(Rockwe ll Medical Inc) until such time as the product becomes commercially available.  
 
 20 6. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
6.1. Discontinuation of Study Interventio n 
In rare instances, it may be necessary for a participant to discontinue study intervention. If study 
intervention is discontinued, the pa rticipant will not remain in the study. See the schedule of 
events  for data to be collected at the time of discontinu ation of study intervention and follow-up 
and for any further evaluations that need to be completed.  
6.1.1. Temporary Discontinuation 
Should a subject develop symptoms of intolerability, the infusion should be immediately 
stopped, and a serum sample should be obtained for iron profile.  The event should be reported 
as an adverse event.  If the adverse event is mild to moderate in severity and recovery has occurred, the patie nt may be rechallenged at the next HD treatment  
6.1.2. Rechallenge  
If the adverse event leading to  temporary discontinuation is mild to moderate in severity and 
required no intervention, the subject may be rechallenged at the next HD treatment.  If the event recurs, the subject must be permanently discontinued form the study. 
6.2. Participant Discontinuation/ Withdrawal from the Study  
• A participant  may w ithdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the investigator  for safety, behavioral, or 
compliance reasons . This is expected to be uncommon. 
• At the time of discontinuing from the study, if possible, an early discontinuation visit 
should be conducted, as shown in the SoE . See So E for data to be collected at  the time of 
study discontinuation and follow-up and for any further evaluations that need to be completed . 
• The participant  will be permanently discontinued both from the study intervention and 
from the study at that time . 
• If the participant  withdraws cons ent for disclosure of future information, the sponsor may 
retain and continue to use any da ta collected before such a withdrawal of consent . 
• If a participant withdraws from the study, he/she may request destruction of any samples taken and not tested, and the investigator must document this in the site study records. 
6.3. Lost to Follow  up 
Not applicable for this study 
 
 21 7. Study Assessments and Procedures  
• Study procedures and their timing are summarized in the Schedule of Events (SoE). 
• Immediate  safety concerns  should be discussed with the sponsor immediately upon 
occurrence or awareness to determine if t he participant should continue or discontinue 
study intervention. 
• Adherence to the study design requirements, including those specified in the SoE, is 
essential and required for study conduct. 
• All screening evaluations must be completed and reviewed to con firm that potential 
participant s meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participant s screened and to confirm eligibility or rec ord reasons for 
screening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management (e .g., blood 
count) and obtained before signing of the ICF may be utilized for screening or baseline 
purposes provided the procedures met the protocol- specified criteria and were performed 
within the time frame defined in the Schedule of Events. 
• The maximum amount of blood collected from each participant over the duration of the study, including any extra assessments that may be required, will not exceed  70 mL.  
• Repeat or unscheduled samples may  be taken for safety reasons or for technical issues 
with the samples . 
7.1. Efficacy Assessments 
Planned time points for all efficacy assessments are provided in the Schedule of Events. 
7.2. Safety Assessments  
Planned time points for all safety assessments are provided in the Schedule of Events. 
7.2.1. Physical Examinations 
• A brief physical examination will include, at a minimum, assessments of the skin and cardiovascular system (BP heart rate) . 
• Investigators should pay special attention to clinical signs related to previous serious illnesses.  
7.2.2. Vital Signs  
• Temperature, pulse r ate, respi[INVESTIGATOR_697], and blood pressure will be assessed according to 
the site protocol at the start and end of each HD  
7.2.3. Clinical Safety Laboratory Assessments 
• See the Schedule of Events (Section 1.3) for the timing and frequency of laboratory sample collection  
 
 22 7.2.4. Pregnancy Testing  
Female subjects of child -bearing potential should be tested if pregnancy is possible. 
7.3. Adverse Events  (AEs), Serious Adverse Events  (SAEs), and Other 
Safety Reporting  
The definitions of adverse events (AEs) and s erious a dverse events (SAEs)  can be found in 
Section 8.3. 
AEs will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally authorized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study intervention or study procedures, or that 
caused the participant to discontinue the Triferic AVNU  (see Section 0).  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the procedures for completing and transmitting SAE reports are provided in Section 8.3. 
7.3.1. Time Period and Frequency for Collecting AE and SAE Information  
All AEs  and SAEs  will be collected from the start of intervention] until the follow up visi t at 
study termination at the time points specified in the Schedule of Events ( Section  1.3).  
All SAEs will be recorded and reported to the sponsor or designee immediately and under no circumstance should this exceed 24 hours, as indicated in Section 7.3. The investigator will submit any updated SAE data to the sponsor within 24 hours of it being available. 
Investigators are not obligated to actively seek information on AEs or SAEs after conclusion of 
the study par ticipation . However, if the investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she considers the event to be 
reasonably related to the study intervention or study participation, the investigator must promptly 
notify the sponsor. 
7.3.2. Method of Detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open- ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about AE occurrences . 
7.3.3. Follow- up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visi ts/contacts. All SAEs  will be followed until resolution, stabilization, the event 
is otherw ise explained, or the participant is lost to follow-up. Further information on follow-up 
procedures is provided in  Section  7.3.3. 
 
 23 7.3.4. Regulatory Reporting Requirements for SAEs  
• Prompt notification by [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of 
a study intervention under clinical investigation are met.  
• The sponsor has a legal responsibility to notify both the local r egulat ory authority and 
other regulatory agencies about the safety of a study intervention under clinical investigation. The sponsor will comply with regulatory requirements relating to safety reporting to the regulatory authority and  Institutional Review Boards (IRB) . 
• An investigator who receives an investigator safety report describing an SAE or other specific safety information (e.g., summary or listing of SAEs) from the sponsor will review and then file it along with the package insert and will notify t he IRB /IEC, if 
appropriate according to local requirements. 
7.3.5. Pregnancy  
• Details of all pregnancies  will be collected after the start of study intervention and unti l 
delivery . 
• If a pregnancy is reported, the inves tigator will record pregnancy information on the 
appropriate form and submit it to  the sponsor within 3 days of learning of the [female 
participant or female partner of male participant (after obtaining the necessary signed informed consent from the female partner )] pregnancy. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
• Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considere d SAEs a nd will be reported as 
such. 
• The participant will be followed to determine the outcome of the pregnancy. The investigator will collect follow -up information on the participant and the neonate and the 
information will be forwarded to the sponsor. 
• Any post-study pregnancy-related SAE considered reasonably related to the study 
intervention by [CONTACT_55901]  7.3.4. While the investigator is not obligated to ac tively seek this information in 
former study participants, he or she may learn of an SAE through spontaneous reporting. 
• Any female participant who becomes pregnant w hile participating in the study may  
request to continue in the study.  Prior to continuation of study intervention following pregnancy, the following must occur: 
• The sponsor and the relevant IRB/IEC give written approval. 
• The participant gives signed informed consent. 
• The investigator agrees to monitor the outcome of the pregnancy and the status of the participant and her offspring. 
 
 24 7.3.6. Disease -Related Events and/or Disease- Related Outcomes Not 
Qualifying as AEs or SAEs 
The following disease- related events (DRE s) are common in participants with end -stage kidney 
failure on chronic hemodialysis and can  be serious/life threatening: 
• Myocardial Infarction  
• Stroke 
• Hypertension 
• Intradialytic hypotension 
• Vascular access clotting or failure  
Because these events are typi[INVESTIGATOR_103659], they will not be 
reported according to the standard process for expedited reporting of SAEs even though the 
event may meet the definition of a n SAE.  
NOTE: However, if either of the following conditions applies, then the event must be recorded and reported as an AE/SAE (instead of a DRE):  
The event is , in the investigator’s opi[INVESTIGATOR_1649], of greater intensity, frequency, or duration than 
expected for the individual participant. 
OR 
The investigator considers that there is a  reasonable possibility that the event was related to study 
intervention. 
7.3.7. Medical Device Deficiencies  
Medical devices are being provided for use in this study as the study intervention. T o fulfill 
regulatory reporting obligations worldwide, the investi gator is responsible for the detection and 
documentation of events meeting the definitions of device deficiency  that occur during the study 
with such devices. 
The definition of a Medical Device deficiency  can be found in Section 8.4. 
NOTE: Deficiencies  fulfilling the definition of an AE/SAE will follow the processes o utlined in 
Section 7.3.7 of the protocol.  
[IP_ADDRESS]. Time Period for Detecting Medical Device Deficiencies  
• Medical device deficiencies  that result in an incident will be detected, documented, and 
reported during all periods of the study in which the m edical device is used.  
• If the inv estigator learns of any device deficiency  at any time after a participant has been 
discharged from the study, and such a deficiency  is considered reasonably related to a 
medical device provided for the study, the investigator will promptly notify the sponsor. 
The method of documenting Medical Device Deficiency  is provided in Section 8.4. 
[IP_ADDRESS]. Follow- up of Medical Device Deficiencies  
• Follow-up applies to all participants, including those who discontinue study intervention. 
 
 25 • The investigator is responsible for ensuring that follow-up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality of the deficiency . 
• New or updated information will be recorded on t he originally completed form with all 
changes signed and dated by [CONTACT_093]. 
[IP_ADDRESS]. Prompt Reporting of Device Deficiencies  to Sponsor 
• Device deficiencies will be reported to the sponsor within 24 hours after the investigator determines that the event meet s the protocol definition of a medical device deficiency. 
• The Medical Device Deficiency Repor t Form will be sent to the sponsor by [CONTACT_71345] .  
• The sponsor will be the contact [CONTACT_31841].  
[IP_ADDRESS]. Regulatory Reporting Requirements for Device Deficiencies  
• The investigator will promptly report all device deficiencies  occur ring with any medical 
device provided for use in the study in order for the sponsor to fulfill the legal responsibility to notify appropriate regulatory authorities and other entities about certain safety information relating to medical devices being used in clinical studies.  
• The investigator, or responsible person according t o local requirements ( e.g., the head of 
the medical institution), will comply with the applicable local regulatory requirements relating to the reporting of device deficiencies  to the IRB/IEC.  
7.4. Pharmacokinetics  
• Serum samples of approximately 4.5 mL will be collected for measurement of serum iron, TSAT , TIBC and Ferritin concentrations as specified in the Schedule of Events 
(Section 1.3)
at the start of hemodialysis and at the end of t he Triferic AVNU infusion.  
• A maximum of 2 samples may be collected at additi onal time points during the study if 
warranted and agreed upon between the investigator and the sponsor. The timing of sampling may be altered during the course of the study based on newly available data (e.g., to obtain data closer to the time of peak pla sma concentrations) to ensure 
appropriate monitoring.  
• Instructions for the collection and handling of biological samples will be provided by [CONTACT_456]. The actual date and time (24 -hour clock time) of each sample will be recorded.  
• Samples will be used to evaluate the delivery of iron from Triferic AVNU  using the 
Freedom Edge pump.  
Pharmacodynamic parameters are not evaluated in this study. 
7.5. Genetics  and/or Pharmacogenomics  
Genetics are not evaluated in this study. 
7.6. Biomarkers  
Biomarkers are not evaluated in this study. 
 
 [ADDRESS_1220605] exploratory economic analyses and will include: 
• Number and duration of medical care encounters, for Triferic  AVNU infusion using the 
Freedom Edge pump. 
• Time to withdraw Triferic AVNU from ampule  
• Time  to set up Freedom Edge Pump 
• Nursing time to monitor pump performance. 
7.9. Statistical Hypotheses  
7.10. Sample Size Determination  
The sample size is empi[INVESTIGATOR_873939] a feasibility study. 
7.11. Analysis Sets  
Participant Analysis Set  Description  
Safety All participants who are exposed to study intervention . 
Participants will be analyzed according to the intervention they 
actually received.  
7.12. Statistical Analyses  
All parameters obtained will be presented as summary statistics.  No hypothesis testing will be performed.  
7.12.1. General Considerations 
All data collected will be summarized.  
7.12.2. Primary Endpoint(s)  
The primary endpoint will be the change in serum iron concentration f rom pre -dialy sis to the end 
of infusion. 
7.12.3. Secondary E ndpoint(s)  
The secondary  endpoints will be the change in serum iron transferrin saturation (TSAT) 
concentration form pre-dialysis to the end of infusion. 
 
 27 7.12.4. Safety  Analy sis 
All safety analyses will be made on the Safety Population. 
7.12.5. Other Analys is 
The performance of the Freedom Edge pump will be assessed by [CONTACT_873952]-and 
motion assessment.  
 
 
 28 8. Supporting Documentation and Operational Considerations  
8.1. Regulatory, Ethical, and Study Oversight Considerations  
8.1.1. Regu latory and Ethical Considerations 
• This study will be conducted in accordance with the protocol and with the following: 
o Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines  
o Applicable ICH Good Clinical Practice (GCP) Guidelines  
o Applicable laws and regulations 
• The p rotocol, protocol amendments, ICF, Investigator Brochure, [ID FU] and other 
relevant documen ts (e.g., advertisements) must be submitted to an IRB/IEC by [CONTACT_52009]/IEC before the study is initiated. 
• Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an 
immediate hazard to study participants.   
• Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation except for changes ne cessary to eliminate an immediate 
hazard to study participants. 
• The investigator will be responsible for the following: 
o Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/IEC 
o Notifying the IRB/IEC of SAEs or other significant safety findings as required by [CONTACT_1744]/IEC procedures 
o Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), European Medical Device Regulation 2017/745 for clinical device research (if applicable), and all other applicable local regulations 
8.1.2. Financial Disclosure  
Investigators and sub- invest igators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certific ation or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study. 
8.1.3. Informed Consent Process  
• The investigator or his/her representative will explain the nature of the study to the 
participant  and answer all questions regarding the study. 
 
 29 • Participants must be informed that their participation is voluntary. Participants ] will be 
required to sign a statement of informed consent that meets the requirements of [ADDRESS_1220606] (HIPAA) requirements, where applicable, and the IRB/IEC or study center. 
• The medical record must in clude a statement that written informed consent was obtained 
before the participant was enr olled in the study and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF. 
• Participants must be r e-consented to the most current version of the ICF(s) during their 
participation in the stu dy. 
• A copy of the ICF(s) must be provided to the participant <End of common text> 
8.1.4. Data Protection 
• Participants will be assigned a unique identifier by [CONTACT_148606]. Any participant 
records or datasets that are transferred to the sponsor will contain the identifier only; participant names or any information which would make the participant identi fiable will 
not be transferred. 
• The participant must be informed that his/her personal study- related data will be used by 
[CONTACT_10999]. The level of disclosure must also be explained to the participant  who will be required to give consent for their data to 
be used as described in the informed consent  
• The participant must be informed that his/her medical records may be examined by [CONTACT_340764], by [CONTACT_6667]/IEC members, and by [CONTACT_6668]. 
8.1.5. Committees Structure  
There will be no a dditional committees for this study . 
8.1.6. Dissemination of Clinical Study Data 
The posting of company-sponsored study information and tabular study results on the US 
National Institutes of Health’s website  www.ClinTrial s.gov and other publicly- accessible sites . 
8.1.7. Data Quality Assurance 
• All participant data relating to the study will be recorded on printed CRF unless 
transmitted to the sponsor or designee electronicall y (e.g., laboratory data). The 
investigator is responsible for verifying that data entries are accurate and correct by [CONTACT_1189]. 
• The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulato ry agency inspections and provide direct access to sourc e data documents.  
• The sponsor or designee is responsible for the data management of this study including quality checking of the data. 
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by [CONTACT_1732] 1 years after study completion unless local 
 
 30 regulations or institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of the sponsor. No records may be transferred to  another location or party without written notification to the 
sponsor. 
8.1.8. Source Documents  
• Source documents provide evidence for the existence of the participant and substantiate the integrity of the da ta collected. Source documents are filed at the investig ator’s site.  
• Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or tr ansfer 
records, depending on the study. Also, current medical records must be available. 
• Definition of what constitutes source data can be found in Section 8.1.8. 
• The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
• Study monitors will perform ongoing source data verification to confirm t hat data entered 
into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements. 
8.1.9. Study and Site Start and Closure  
First Act of Recruitment  
The study start date is the date on which the clinical study will be open for recruitment of 
participants.  
The first act of recruitment is the study start date.  
Study/Si te Termination  
The sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study- site closure visit has been performed. 
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_11004]:  
For study termination: 
• Discontinuation of further study intervention development 
For site termination:  
 
 31 • Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC 
or local heal th authorities, the sponsor's procedures, or GCP guidelines 
• Inadequate or no recru itment (evaluated after a reasonable amount of time)  of participants 
by [CONTACT_093] 
• Total number of participants included earlier than expected 
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_873953]. The investigator shall promptly inform the participan t and should assure 
appropriate participant  therapy and/or follow-up 
8.1.10. Publication Policy  
• The results of this study may be published or presented at scientific meetings. If thi s is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor 
before submission. This allows the sponsor to protect proprietary information and to provide comments. 
• The sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator [INVESTIGATOR_12992]. 
• Authorship will be determined by [CONTACT_23531].  
8.2. Clinical Laboratory Tests  
• The tests detailed in Table 1 will be performed by [CONTACT_2237] . 
• Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_11006]. 
Tabl e 1: Protocol-Required Safety Laboratory Tests  
Laboratory 
Tests  Parameters  
Clinical 
Chemis try1 Serum iron concentration (sFe)  TSAT  Ferritin  TIBC  
Pregnancy testing  • Highly sensitive [Serum or urine]  human chorionic gonadotropin 
(hCG) pregnancy test (as needed for women of childbearing potential)
[ADDRESS_1220607] document their review of each laboratory safety report. 
  
 
 32 8.3. AEs and SAEs : Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  
8.3.1. Definition of AE  
AE Definition  
• An AE is a ny untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention. 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. 
Definition of Unsolicited and Solicited AE  
• An unsolicited adverse event is an adverse event that was not solicited usi ng a 
Participant Diary and that is communicated by a [participant/participant’s 
parent(s)/LAR(s)] who has signed the informed consent. Unsolicited AEs include serious and non- serious AEs.  
• Potential unsolicited AEs may be medically attended (i.e., symptoms or illnesses 
requiring a hospi[INVESTIGATOR_11956], or emergency room visit, or visit to/by a health care 
provider). The [participants/ participa nt’s parent(s)/LAR(s)] will be instructed to 
contact [CONTACT_285147](s), as well as any 
events that, though not medically attended, are of [participant/ parental /L AR’s] 
concern. Detailed information about reported unsolicited AEs will be collected by 
[CONTACT_14348]’s records. 
• Unsolic ited AEs that are not medically attended nor perceived as a concern by 
[participant/participant’s parent(s)/LAR(s)] will be collected d uring interview with the 
[participants/participant’s parent(s)/LAR(s)]  and by [CONTACT_285149].  
• Solicited AEs are predefined local [at the injection site]  and systemic events for which 
the participant is specifically questioned, and which are noted by [CONTACT_139140].  
 
Events Meeting the AE Definition  
• Any abnormal labora tory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessmen ts (e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical and scienti fic judgment of the investigator (i.e., not related to progression of 
underlying disease). 
• Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition. 
 
 33 • New conditions detected  or diagnosed after study intervention administration even 
though it may have been present before the start of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected intervention- intervention 
interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Over dose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae. 
 
Events NOT  Meeting the AE D efinition  
• Any clinically significan t abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by [CONTACT_873954]’s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant’s condition. 
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospi[INVESTIGATOR_307]). 
• Anticipated day -to-day fluctuations of pre- existing disease(s) or con dition(s) present or 
detected at the start of the study that do not worsen. 
8.3.2. Definition of SAE  
An SAE is defined as any serious adverse event  that, at any dose: 
a. Results in death 
b. Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe. 
c. Requires inpatient hospi[INVESTIGATOR_5186] n or prolongation of existing hospi[INVESTIGATOR_059] 
• In general, hospi[INVESTIGATOR_125403] e participant has been admitted  (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_12332]/or treatment that would not have been  appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
 
 34 serious. When in doubt as to whether  “hospi[INVESTIGATOR_059]” occurred or was necessary, the 
AE should be considered serious. 
• Hospi[INVESTIGATOR_159200] a pre -existing condition that did not worsen 
from baseline is not considered an AE. 
d. Results in persistent  or significant  disabilit y/inc apacity 
• The term disability means a substantial disruption of a person’s ability to co nduct 
normal life functions. 
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption. 
e. Is a congenital anomaly/birth defect  
f. Is a suspected transmission of any infectious agent via an authorised medicinal product  
g. Other situations: 
• Medical or scient ific judgment should be exercised by [CONTACT_873955] y jeopardize the participant or may require medical or surgical 
intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious. 
o Examples of such events include invasive or malignant cancers, intensive treatment for allergic bronchospasm, blood dyscrasias, convulsions or development of intervention dependency or intervention abuse.
 
8.3.3. Recording and Follow-U p of AE and/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibilit y of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) related to the event.  
• The investigator will then record all relevant AE/SAE information . 
• There may be instances when copi[INVESTIGATOR_29482]. In this case, all participant identifiers, with the exception of the participant number, will be redacted on the copi[INVESTIGATOR_873940] e Sponsor. 
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.  
 
 35 Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to 1 of the following categories:  
• Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort 
and not interfering with everyday a ctivities.  
• Moderate: An event that causes sufficient discomfort to  interfere with normal ev eryday 
activities.  
• Severe: An event that prevents normal everyday activities. An AE that is assessed as severe should not be confused with an SAE. Severe is a catego ry utilized for rating the 
intensity of an event; and both AEs and SAEs can be assessed as severe.  
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe. 
 
Assessment of Causality  
• The investigator is obligated to assess the relationship betwe en study intervention and 
each occurrence of each AE/SAE.  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
• The investigat or will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study intervention administration will be cons idered and investigated. 
• The investigator will also consult the Investigator’s Brochure (IB) and/or Product Information, for marketed products, in his/her assessment. 
• For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations  in which an SAE has occurred, and the investigator has 
minimal information to in clude in the initial report. However, it is very important that 
the investigator always mak e an assessment of causality for every event before the 
initial transmission of the SAE data to Rockwell Medical Inc. . 
• The investigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send an SAE follow-up report with the upda ted causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting requirements.  
 
 
 36 Follow- up of AEs and SAEs  
• The i nvestigator is obligated to perform or arrange for the conduct of supplemental 
measurements  and/or evaluations as medically indicated or as requested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals. 
• New or updated information will be recorded in the originally submitted documents. 
• The investigator will submit any updat ed SAE data to Sponsor within 24 hours of 
receipt of the information.  
8.3.4. Reporting of SAEs 
SAE Reporting to  Sponsor via Paper Data Collection Tool 
• Facsimile transmission of the SAE paper data collection tool  is the preferred method 
to transmit this information to t he Medical monitor . 
• Medical Monitor: Contact [CONTACT_873956] D Pratt, MD  
Chief  Development Officer  
Email: [EMAIL_16581]  
Fax: [PHONE_18105] 
8.4. AEs, ADEs, SAEs, SADEs, [LOCATION_003]DEs and Device Deficie ncies: 
Definitions and Procedures for Recording, Evaluating, Follow -up, 
and Reporting in Me dical Device Studies  
• The definitions and procedures detailed in this section  are in accordance with ISO [ZIP_CODE] 
and European Medical Device Regulation (MDR) 2017/745 f or clinical device research 
(if applicable ).  
• Both the investigator and the sponsor will comply with all local reporting requirements 
for medical devices. 
• The detection and documentation procedures described in this protocol apply to all sponsor medical devices provided for use in the study. See Section 5.1.[ADDRESS_1220608] of sponsor medical devices. 
 
8.4.1. Definition of  Medical Device AE and ADE  
Medical Device AE  and ADE  Definition   
• An AE is any untoward medical occur rence in a clinical study  participant, users, or 
other persons, temporally associated with the use of study intervention, whether or not 
considered related to the investigational medical device . An AE can therefore be any 
unfavorable and unintended sign (i ncluding an abnormal laboratory finding),  symptom, 
 
 37 or disease (new or exacerbated) temporal ly associated with the use of an 
investigational medical device . This definition includes events related to the 
investigational medical device or comparator and even ts related to the procedures 
involved. 
• An adverse device effect (ADE) is defined as an AE related to the use of an 
investigational medical device. This definition includes any AE  resulting from 
insufficient or inadequate instructions for use, deployment, i mplantation, installation, 
or operation, or any malfunction of the investigational medical device as well as any 
event resulting from use error or from intentional misuse of the investigational medical device.  
8.4.2. Definition of  Medical Device SAE, SADE and [LOCATION_003]DE  
A Medical Device SAE  is an any serious adverse even t that : 
a. Led to death  
b. Led to serious deteriorat ion in the health of the participant, that either resulted in : 
• A life -threatening illness or injury. The term “ life-threatening ” in the definition of 
“serious” refers to an event in which the participant was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death if it were more severe. 
• A permanent impairment of a body structure or a body func tion. 
• Inpatient or prolonged hospi[INVESTIGATOR_059]. Planned hospi[INVESTIGATOR_272] a pre-existing condition, or a procedure required by [CONTACT_760], without serious deterioration in 
health, is not considered an SAE. 
• Medical or surgical intervention to prevent life- threat ening illness or injury or 
permanent impairment to a bo dy structure or a body function. 
• Chronic disease (MDR 2017/745). 
c. Led to fetal distress, fetal death , or a congenital abnormality or birth defect  
d. Is a suspected transmission of any infectious a gent vi a a medicinal product  
SADE definition  
• A SADE is defined  as an adverse device effec t that has resulted in any of the 
consequences characteris tic of a n SAE . 
• Any device deficiency that might have led to an SAE  if appropriate action had not been 
taken , intervention had not occurred, or circumstances had been less fortunate. 
Unanticipated SADE ( [LOCATION_003]DE ) definition  
 
 38 • An [LOCATION_003]DE (also identified as UADE in US Regulations 21 CFR 813.3), is defined as 
a serious adverse device effect that  by [CONTACT_5942], incidenc e, severity , or outcome has 
not been identified in the current version of the risk analysis report (see Section 8.3.3).  
8.4.3. Definition of Device Deficiency  
Device Deficiency Definition  
• A device deficiency  is an inadequacy  of a medical device with respect to its identity, 
quality, durability, relia bility,  safety, or performance.  Device deficiencies include 
malfunctions, use errors, and information supplied by [CONTACT_3455]. 
8.4.4. Recording and Follow- Up of AE and/or SA E and Device Deficiencies  
AE, SAE , and Device Deficiency Recording  
• When an AE/SAE/device d eficiency occurs, it is the responsibility of the investigator 
to review all documentation (e.g., hospi[INVESTIGATOR_1088], laboratory reports, and 
diagnostics report s) related to the event.  
• The investigator will then record all relevant AE/SAE/device defic iency information in 
the participant’s medical records, in accordance with the investigator’s normal clinical practice and on the appropriate form.  
• It is not  acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records in lieu of completion of the AE/SAE/device deficiency form . 
• There may be instances when copi[INVESTIGATOR_29482]. In this case, all participant identifiers, with the exception of the participant number, will be redact ed on the copi[INVESTIGATOR_12997]. 
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.  
• For device deficiencies, it is very important that the investigator describes any corrective or remed ial actions ta ken to prevent recurrence of the deficiency.  
o A remedial action is any action other than routine maintenance or servicing of a medical device where such action is necessary to prevent recurrence of a device deficiency. This includes any amendm ent to the dev ice design to prevent 
recurrence.  
 
 
Assessment of Intensity  
The investigator will make an  assessment of intensity for each AE/SAE /device deficiency  
reported during the study and assign it to one of the following categories:  
 
 39 • Mild: An event that is easily  tolerated by [CONTACT_2299], causing minimal discomfort 
and not interfering with everyday activities.  
• Moderate: An event that causes sufficient discomfort and interferes with normal 
everyday act ivities.  
• Severe: An event that prevents normal everyday acti vities. An AE that is assessed as 
severe should not be confused with an SAE. “ Severe” is a category used  for rating the 
intensity of an event; both AEs and SAEs can be assessed as severe. 
• An event is defined as ‘serious’ when it meets at least 1 of the pre defined outcomes as 
described in the definition of an SAE, not  when it is rated as severe.  
 
Assessment of Causality  
• The investigator is obligated to assess the relationship between study  intervention and 
each occurrence of each AE/SAE/device deficiency . 
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a relationship, cannot be ruled out. 
• The investigator will use clinical judgment to determine the relationsh ip. 
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated. 
• The investigator will also consult the Product Information in his/her assessment.  
• For each AE/SAE/device deficiency, the in vestigator must  document in the medical 
notes that he/she has reviewed the AE/SAE /device deficiency and has provided an 
assessment of causality.  
• There may be situati ons in which an SAE has occurred and the investigator has 
minimal information to include in  the initial report to Sponsor. However, it is very 
important that the investigator always make an assessment of causality for every event before the initial transmission of the SAE data to Sponsor. 
• The investigator may change his/her opi[INVESTIGATOR_9242]-up information and send an SAE follow-up report with the updat ed causality assessment.  
• The causality assessment is one of the criteria used when d etermining regulatory 
reporting requirements.  
 
 
Follow- up of AE/SAE/device deficiency  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [X] to 
 
 40 elucidate the nature and/or causality of the AE/SAE/device deficiency as fully as 
possible. Th is may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care professionals. 
• New or updated information will be recorded in the originally completed form . 
• The investigator will submit a ny updated SAE data to the Sponsor within 24 hours of 
receipt of the information.  
8.4.5. Reporting of SAEs 
SAE Reporting to Sponsor via Paper Data Collection Tool 
• Facsimi le or email transmission of the SAE paper data collection tool is the preferred 
method to t ransmit this information to the medical monitor.  
• Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE paper data collection tool within the designated reporting time frames.  
8.4.6. Reporting of SADEs  
SADE  Reporting  to Sponsor ]  
NOTE: There are additional reporting obligations for medical device deficiencies  that are 
potentially related to SAEs that must fulfill the legal responsibility to notify appropriate 
regulatory authorities and other entities about certain safety information relating to medical devices being used in clinical studies.  
• Any device deficiency that is associated with an SAE must be reported to the s ponsor 
within 24 hours after the investigator determines that the event meets the definitio n of a 
device deficiency.  
• The sponsor wi ll review all device deficiencies and determine and document in writing 
whether they could have led to an SAE. These device deficiencies will  be reported to 
the regulatory authorities and IRBs/IECs as required by [CONTACT_2091]. 
• Contacts for SAE reporting: 
Raymond D Pratt, MD 
Chief Development Officer  
Email: rpratt@rockweellmed .com  
Fax: [PHONE_18105]. 
  
 
 41 8.5. Protocol Amendment History 
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC). 
Amendment [amendment number] :  
This amendment is considered to be subst antial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union. 
Overall Rationale for the Amendment  
 
Section # and Name [CONTACT_23688] 
   
   
   
 
 42 9. Triferic AVNU US PI  
[INVESTIGATOR_873941]  
 
 
 43 10. Freedom Edge Pump  
See Attached Freedom Pump Document  